Our mission is to develop the most effective and safest formulation for Paclitaxel (MewTaxol) for cancer treatment.
New Co (MewTaxol Inc.) has developed a new Hybrid Paclitaxel (MewTaxol) to treat cancer with its double edge mode of action. The Company has developed the hybrid drug MewTaxel which is ready for clinical trials. Our 1st exit plan is $100-500M within 5 years.
Since the discovery of this hybrid platform NewCo has been investing its resources to develop a better, or I would say the best, formulation of Hybrid Paclitaxel (MewTaxol). NewCo always look for a better solution for cancer treatment. At this point, Mewtaxol needs funds for clinical trials and FDA filing.
Our office is located in Baton Rouge, LA70791. The company has its collaborations with Meda Biotech LLc., USA and Nano Biotech (P) Ltd., India.
Currently, about 30% of drugs that appear on the World Health Organization (WHO) Essential Drug List were reported to have poor water-solubility, based on the Biopharmaceutics Classification System (BCS).
Over 40% of newly developed pharmaceutically active substances have solubility issues. The poor dissolution and/or permeability of these drugs often results in low and highly variable bioavailability.
The major obstacle of successfully commercializing these compounds is the difficulty of enhancing their dissolution rate and extent of dissolution Paclitaxel molecule discovered in 1960s through NCI program (Wani and Wall).
1992 : FDA approval of Taxol (paclitaxel)
The best new cancer drug in 30 years
Extracted from bark of the Pacific Yew Tree, extremely insoluble
Formulated with surfactant Cremophor - polyoxyethylated castor oil + ethanol for IV administration
Causes Anaphylaxis and respiratory arrest, and severe hypersensitivity
Poor pharmacokinetic profile is still a problem
High levels of neutropenia and long lasting neuropathy
We believe there is still a lot of room to make this novel drug better than the newest formulation called Abraxane, as well as all other formulations. So we came up with MewTaxol. Exclusive licensing agreements are signed to use the technology for MewTaxel, and each receives a royalty on the net selling price.
MewTaxel is the newest discovery for Hybrid Paclitaxel. It has a potential to beat existing formulations, thereby entering the $4.9 billion cancer treatment market.
MewTaxel is a patented Hybrid Paclitaxel drug which exploits the intact properties of two drugs to achieve a safe, solvent free, surfactant free and protein free water soluble formulation. Mewtaxol is a more potent and safe formulation. The drug is easy to manufacture and easy to administer. Open field to enter.
Major competition is a newly approved protein conjugated Paclitaxel named Abraxane, our hybrid MewTaxol should be a better choice for future. A double edge approach to treat cancer.
Paclitaxel is already approved for Breast cancer, Lung cancer, ovarian cancer, Kaposi sarcoma and Pancreas cancer.
Many ongoing trials are in combination with other drugs, and this will lead to a bigger market expansion.
A double edge approach should be a winner.
Mewa Singh, 609-902-7128, email@example.com
Proof of concept, R&D and pilot scale production procedures are in place, no more dead investment is needed.
A Total of $10-25M is needed to take this drug for FDA submissions and clinical phase.